LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

AZN

185.74

-0.75%↓

Home・Stock List・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Open

SectorHealthcare

68.96 0.12

Buy Sell

Overview

Share price change

24h

Current

Min

67.95

Max

69.53

Key metrics
By Trading Economics
Income	292M 150M
Sales	-75M 377M
P/E Sector Avg	24.112 50.102
EPS	1.221
Profit margin	39.832
Employees	423
EBITDA	-63M 218M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+17.8% upside

Dividends
By Dow Jones
Next Earnings	4 Aug 2026

Market Stats
By TradingEconomics
Market Cap	501M 8.2B
Previous open	68.84
Previous close	68.96

News Sentiment

By Acuity

12%

88%

13 / 344 Healthcare

Halozyme Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

26 May 2026, 16:52 UTC

Major News Events

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 May 2026, 23:57 UTC

Earnings

Sociedad Quimica 1Q Rev $1.76B >SQM

26 May 2026, 23:57 UTC

Earnings

Sociedad Quimica 1Q EPS $1.28 >SQM

26 May 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 May 2026, 21:54 UTC

Earnings

Webco Industries 3Q EPS $11.61 >WEBC

26 May 2026, 21:54 UTC

Earnings

Webco Industries 3Q Sales $179.6M >WEBC

26 May 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 May 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26 May 2026, 20:58 UTC

Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 May 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 May 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26 May 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26 May 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 May 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 May 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 May 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 May 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26 May 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 May 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26 May 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 May 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 May 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 May 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 May 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 May 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26 May 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26 May 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

26 May 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 May 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 May 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Peer Comparison

Price change

Halozyme Therapeutics Inc Forecast

Price Target

By TipRanks

17.8% upside

12 Months Forecast

Average 80.48 USD 17.8%

High 96 USD

Low 66.41 USD

Based on 5 Wall Street analysts offering 12 month price targets forHalozyme Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Halozyme Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

13 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.